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Objective. Vascular abnormalities represent the
main component of the pathobiology of systemic sclero-
sis (SSc), progressing from structural derangements of
the microcirculation with abortive neoangiogenesis to
final vessel loss. Since circulating endothelial progeni-
tor cells (EPCs) are important in the vascular repair
process, we undertook this study to examine their
numbers in the peripheral blood (PB) of SSc patients
and to evaluate whether their status is related to
impaired quantitative and/or qualitative aspects of the
bone marrow (BM) microenvironment.
Methods. Circulating EPCs from 62 SSc patients
were evaluated by flow cytometry and characterized as
CD45 negative and CD133 positive. BM EPCs, identi-
fied as CD133 positive, were isolated from 14 SSc
patients and grown to induce endothelial differentia-
tion. In addition, progenitor numbers and functional
properties of hematopoietic and stromal compartments
were analyzed by various assays.
Results. We found that EPCs were detectable in
the PB of patients with SSc, and their number was
significantly increased in patients with early-stage dis-
ease but not in those with late-stage disease. All of the
examined BM samples contained reduced numbers of
EPCs and stromal cells, both of which were functionally
impaired. Both endothelial and stromal progenitors
expressed vascular endothelial growth factor receptor,
indicating that BM is strongly induced to differentiate
into the endothelial lineage; furthermore, only BM
EPCs from patients with early disease led to endothelial
differentiation in vitro.
Conclusion. This study provides the first demon-
stration that in SSc, there is a complex impairment in
the BM microenvironment involving both the endothe-
lial and mesenchymal stem cell compartments and that
this impairment might play a role in defective vasculo-
genesis in scleroderma.
Adult bone marrow (BM) is a rich reservoir of
tissue-specific stem and progenitor cells, including a
small population of cells known as endothelial progeni-
tor cells (EPCs). Extensive data gathered over the last
few years show that BM-derived EPCs are present in the
peripheral blood (PB), home to sites of active neovas-
cularization, and differentiate to mature endothelial
cells (ECs) in situ, thus contributing to endothelial
replacement (1).
A number of cytokines and growth factors and
their corresponding surface receptors seem to promote
the mobilization of BM EPCs, although their individual
roles are still unclear. However, it is known that vascular
endothelial growth factor (VEGF), an angiogenic pep-
tide with specific mitogenic activity on EPCs, plays a key
role. It binds to its receptor (VEGF receptor 2
[VEGFR-2]) and mediates the further differentiation of
BM-derived EPCs to mature adherent endothelial
monolayers (2).
The number of circulating EPCs in healthy sub-
jects is relatively low, but this may be influenced by a
variety of factors and pathophysiologic conditions. Se-
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vere tissue ischemia, vascular injury, or tumor growth
are all major stimuli associated with EPC mobilization,
recruitment, and homing. In this context, it has been
reported that the number of circulating EPCs is much
greater in patients experiencing a myocardial infarction
(3) or vascular trauma (4). Moreover, the number and
function of circulating EPCs may be impaired in some
disorders characterized by prolonged chronic endothe-
lial damage, such as chronic coronary artery disease,
hypertension, congestive heart disease, and diabetes
mellitus (5–9). It has therefore been postulated that
impaired vascular repair may contribute to the patho-
genesis of these chronic disorders and that a small
number of EPCs may also be a risk factor for athero-
sclerotic plaque instability (9).
It is well known that the microcirculation is the
main environment of the pathobiologic processes asso-
ciated with systemic sclerosis (SSc), which range from
considerable initial endothelial derangement with capil-
lary thrombosis, to often abortive reparative neoangio-
genesis with abnormal capillary proliferation, and to
almost complete loss of vessels in target tissues (10–12).
We have recently reported the presence of mature
circulating ECs in patients with SSc, which are probably
the result of shedding from affected blood vessel walls,
and we also found that an increased number of EPCs are
detectable in PB, particularly in the early disease stages
(13). In contrast, Kuwana et al (14) found that patients
with SSc have fewer circulating EPCs than do healthy
controls and that the function of the cells is impaired.
Nothing is known about the number, function, or mat-
uration of EPCs in BM from patients with SSc or other
disorders characterized by chronic vascular injury.
The aim of this study was to further investigate, in
a new larger series of patients with SSc, the impaired
vasculogenesis by evaluating the number of EPCs in the
PB during different phases of the disease. Moreover, in
some of these patients, the number and functional
phenotypes of endothelial and stromal progenitor cells
in the BM were also investigated.
PATIENTS AND METHODS
Patients. This study was approved by the local ethics
committee boards, and written informed consent was obtained
from all participants. We studied 62 consecutive patients
fulfilling the American College of Rheumatology (formerly,
the American Rheumatism Association) criteria for SSc (15).
Patients were classified as having limited cutaneous SSc
(lcSSc) or diffuse cutaneous SSc (dcSSc) on the basis of the
criteria of LeRoy et al (16). We excluded patients whose
symptoms overlapped those of other connective tissue dis-
eases. Clinical assessment of the study population was per-
formed according to the criteria previously described (17).
According to those investigators, disease duration was calcu-
lated from the time of the first signs and symptoms related to
SSc (Raynaud’s phenomenon, puffy hands, sclerodactyly with
or without proximal scleroderma, dyspnea, and/or dysphagia).
For all SSc patients, disease activity was assessed using the
activity indexes of the European Scleroderma Study Group
(18,19). According to these criteria, the disease was considered
active if the sum of the scores of detected items was 3.
Disease stages were defined as suggested by Medsger and
Steen (20): for early lcSSc, disease duration 5 years; for
intermediate/late lcSSc, disease duration 5 years; for early
dcSSc, disease duration 3 years; and for intermediate/late
dcSSc, disease duration 3 years.
Thirty-eight of the 62 patients received therapy with
intravenous prostanoid. The blood samples for EPC assay were
always obtained just before the iloprost infusion and at least 1
month after the previous one. Angiotensin-converting enzyme
inhibitors and calcium/channel blockers were discontinued at
least 3 weeks before the study. We excluded pregnant women,
smokers, persons with diabetes or hypertension, patients with
significant hyperlipidemia, and those receiving cholesterol-
lowering medications, including statins. None of the patients
had received any disease-modifying drugs (i.e., corticosteroids,
cyclophosphamide, or methotrexate).
Fifty age- and sex-matched healthy subjects were in-
cluded as controls in the cytofluorometric study of circulating
EPCs. Normal BM samples were collected from 10 healthy
donors (median age 38 years, range 22–46 years) for allogeneic
BM transplantation.
Antibodies. For the immunocytochemical and flow
cytometry analyses, we used fluorescein isothiocyanate
(FITC)–labeled lectins from Ulex europaeus agglutinin type I
(UEA-I; Sigma-Aldrich, Milan, Italy) and the following mono-
clonal antibodies (mAb): anti–factor VIII/anti–von Willebrand
factor (anti-vWF) and anti-CD45 (Dako, Milan, Italy), allo-
phycocyanin (APC)–conjugated anti–kinase insert domain–
containing receptor (anti-KDR) (89106; R&D Systems, Min-
neapolis, MN), anti–Tie-2, anti–E-selectin (anti-CD62E), anti-
CD105, anti–vascular cell adhesion molecule 1 (anti–
VCAM-1) (anti-CD106), anti–platelet endothelial cell
adhesion molecule 1 (anti-CD31), phycoerythrin (PE)–
conjugated anti-CD3, and PE-conjugated anti–nerve growth
factor receptor (anti-NGFR) (C40-1457) (all from BD PharM-
ingen, San Jose, CA), FITC-conjugated anti-CD34 (8G12),
anti-CD14, FITC-conjugated anti-CD14, APC-conjugated anti-
CD19 (SJ25C1), and peridin chlorophyll protein–conjugated
anti-CD45 (2D1) (all from Becton Dickinson, Milan, Italy),
anti–VE-cadherin (anti-CD144) (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-AC133/2 and APC-conjugated anti-
AC133 (293C3) (anti-CD133) (Miltenyi Biotec, Bergisch Glad-
bach, Germany), anti-CD146, FITC-conjugated anti-CD146,
and PE-conjugated anti-CD146 (anti-P1H12) (Chemicon In-
ternational, Temecula, CA), FITC-conjugated anti-CD105
(SN6; Serotec, Oxford, UK), anti–low-affinity NGFR (anti-
LNGFR) (Me20.4; Upstate Biotechnology, Lake Placid, NY),
and FITC-conjugated glycophorin A (Immunotech, West-
brook, ME).
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Flow cytometry studies. Detection of circulating EPCs
by flow cytometry. Circulating endothelial progenitors (de-
fined as CD45-negative and CD34-, VEGFR-2–, and CD133-
positive cells) were detected as previously described (13).
Five-parameter, 3-color flow cytometry was performed using a
FACScan flow cytometer equipped with a 15 mW argon laser,
and the data were analyzed using CellQuest software (Becton
Dickinson, San Jose, CA).
Flow cytometric analysis of BM cells. A total of 2  105
cells were incubated with the selected primary mAb. They were
then evaluated using a FACSCalibur instrument and
CellQuest software (both from Becton Dickinson).
Detection of soluble VEGF. Plasma VEGF concentra-
tions were assessed by commercial enzyme-linked immunosor-
bent assays (R&D Systems). The concentrations were then
calculated using a standard curve generated by specific stan-
dards in accordance with the manufacturer’s recommenda-
tions.
Isolation of BM low-density mononuclear cells
(MNCs). After obtaining informed consent from subjects, an
average of 30 ml of BM from 14 SSc patients and 10 healthy
controls was collected in heparinized tubes and layered on a
Ficoll-Paque gradient (specific gravity 1.077 gm/ml; Nycomed
Pharma, Oslo, Norway). The low-density MNCs were resus-
pended in Iscove’s modified Dulbecco’s medium (IMDM;
BioWhittaker, Caravaggio, Italy) supplemented with 10% fetal
bovine serum (FBS; Cambrex Bioscience, Caravaggio, Italy).
BM CD133-positive cell separation. The hematopoi-
etic stem cells and progenitor cells were isolated by positively
selecting CD133-expressing cells. Briefly, the BM low-density
MNCs were incubated for 30 minutes with the AC133/1 mAb,
directly labeled with microbeads, and placed on a column in
the midiMACS cell separator (Miltenyi Biotec). The labeled
cells were separated using a high-gradient magnetic field and
eluted from the column after their removal from the magnet.
The cells were counted and assessed for viability by trypan blue
dye exclusion, and their purity was determined using a
FACSCalibur flow cytometer.
Cultures of CD133-positive BM cells. A total of 3 
105 CD133-positive enriched cells were plated on fibronectin-
coated T-25 tissue culture flasks (Boehringer Mannheim,
Milan, Italy), grown in M199 medium (Sigma-Aldrich) sup-
plemented with 10% FBS (Cambrex Bioscience), 50 ng/ml
VEGF, 1 ng/ml basic fibroblast growth factor (bFGF), and 2
ng/ml insulin-like growth factor 1 (IGF-1) (all from Peprotech,
London, UK), and cultured to confluence at 37°C in a fully
humidified atmosphere containing 5% CO2.
Purification and expansion of UEA-I ECs. The details
of this procedure have been previously described (21). Briefly,
an average of 2–4  106 cells were incubated with FITC-
labeled lectins from UEA-I and then with anti-FITC micro-
beads (MACS; Miltenyi Biotec) and separated by immuno-
magnetic sorting. Purified cells were cultured in endothelial
medium for 3–4 weeks before characterization.
EC activation. Differentiated ECs were activated by
adding 10 ng/ml interleukin-1 (IL-1; PeproTech) to the
cultures for 4 and 24 hours. The expression of CD62E, CD105,
CD106, vWF, Tie-2, and KDR was evaluated by immunocyto-
chemistry using the alkaline phosphatase–anti–alkaline phos-
phatase (APAAP) technique, as previously described (22).
Positive selection of anti-NGFR antibody–positive
mesenchymal stem cells (MSCs). The details of this procedure
have been previously described (23). Briefly, the low-density
MNCs were incubated with the Me20.4 mAb labeling the
LNGF receptor (or p75NGFR), incubated with anti-IgG1 im-
munomagnetic beads, and placed on a midiMACS column.
The positive fraction underwent a second separation step. The
cells were then counted and assessed for viability, and their
purity was determined by flow cytometry using a PE-
conjugated anti-human NGFR antibody (clone C40-1457)
which reacts with the 75-kd (or low-affinity) subunit of the
nerve growth factor receptor.
Colony-forming units–fibroblastic (CFUs-F). The de-
tails of this procedure have been previously described (24).
Briefly, 1 106 low-density MNCs and 1 105 NGFR-positive
cells from SSc and normal BM were incubated in IMDM and
20% FBS. After 9 days of culture, the flasks were fixed with
methanol and stained with crystal violet. The fibroblast colo-
nies were counted using an inverted microscope at 25
magnification. Cell clusters consisting of 50 fibroblasts were
scored as CFU-F colonies.
Functional assays. Fibroblastic differentiation of
MSCs. In order to induce fibroblastic differentiation, 5  104
LNGFR-positive cells were incubated in IMDM supplemented
with 20% FBS and 10 ng/ml bFGF (PeproTech) in T-25 flasks
and processed as previously described (23). Total expansion
ability was evaluated as the fold increase (i.e., the final
absolute number of cells obtained when all of the starting cells
had expanded to senescence, divided by the number of starting
cells).
Adipogenic, osteogenic, and endothelial differentiation of
MSCs. To induce adipocyte differentiation, 5  104 LNGFR-
positive cells were cultured and characterized as previously
described (25). To induce osteogenic differentiation, 5  104
LNGFR-positive cells were cultured and characterized as
previously described (26,27). To induce endothelial differenti-
ation, 1  105 NGFR-positive enriched cells were plated on
fibronectin-coated T-25 tissue culture flasks in the presence of
specific endothelial medium and then purified with lectins
from UEA-I, as described above.
Long-term BM cultures. Long-term cultures of BM
from the SSc patients and normal controls were established
according to the method of Chang et al (28). BM MNCs (2 
107) were plated in 10 ml of MyeloCult medium (StemCell
Technologies, Vancouver, British Columbia, Canada). The
cultures underwent weekly demipopulation and exchange of
half of the supernatant medium for an equal volume of fresh
medium. The cells in the harvested media were counted and
assayed for progenitor cells by in vitro colony formation.
Stroma formation was evaluated as the percentage of the flask
surface covered by stromal cells, with confluence considered to
represent 100%.
Progenitor assays. The colony-forming unit–
granulocyte–macrophage (CFU-GM) assays were carried out
by plating 5  104 cells in a methylcellulose culture medium
(MethoCult GF H4434; StemCell Technologies). Triplicate
dishes were incubated at 37°C in a fully humidified atmosphere
containing 5% CO2. After 14 days of culture, aggregates of
40 cells were scored as colonies and counted.
Statistical analysis. Circulating EPC levels in SSc
patients and healthy controls were compared using the Mann-
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Whitney U test, and correlations between the number of
circulating EPCs and disease duration were assessed using
Spearman’s rank correlation test. P values less than 0.05 were
considered significant. BM cell surface marker levels were
compared using Student’s 2-tailed t-test for paired data.
RESULTS
Demographic and clinical characteristics of the
SSc patients. The study included 59 women and 3 men
with a median age of 55 years (range 21–72 years); 27 pa-
tients were classified as having lcSSc and 35 as having
dcSSc. The median disease duration was 5.0 years
(range 1–36 years). On the basis of Medsger and Steen’s
criteria (20), 13 of the 27 patients with lcSSc (48.1%)
and 14 of the 35 with dcSSc (40.0%) had early disease.
The presence of Raynaud’s phenomenon was recorded
in all of the patients. Cutaneous ulcers were found in 23
of 62 patients (37.1%). With respect to pulmonary
involvement, 11 of the 62 SSc patients had primary
pulmonary hypertension and 18 had pulmonary fibrosis
with or without pulmonary hypertension. The evaluation
of disease activity according to the European Sclero-
derma Study Group criteria indicated that 21 of the 62
patients had an active disease.
Quantitative studies of PB EPCs. Following the
method initially described by Rafii (29), we identified
EC progenitors in PB by the surface expression of CD34,
VEGFR-2 (KDR), and CD133, a stem cell marker that
is not expressed by mature ECs. The mean number of
circulating EPCs in the SSc patients (2,108 cells/ml, 95%
confidence interval [95% CI] 1,336–2,880) was signifi-
cantly higher than that in the healthy controls (1,027
cells/ml, 95% CI 615–1,439) (P  0.0042) (Figure 1A).
Interestingly, when the patients with SSc were stratified
on the basis of disease duration, the number of circu-
lating EPCs was significantly increased in those with
recent-onset disease (5 years for lcSSc and 3 years
for dcSSc) compared with those with chronic disease
(P  0.0001); in addition, the patients with chronic
disease (either lcSSc or dcSSc) had lower EPC counts
than the healthy controls, but this difference was not
statistically significant (862 cells/ml versus 1,027 cells/ml)
(Figure 1A). There was a close negative correlation
between the number of circulating EPCs and disease
duration (rs  0.412, P  0.0013) (Figure 1B). No
significant correlation with clinical or pathologic para-
meters, namely, digital ulcers, skin and visceral involve-
ment, and disease activity score, was found. No signifi-
cant correlation between EPC counts and concomitant
vascular therapies was noted.
Soluble VEGF analysis. VEGF is known to be a
major angiogenic peptide involved in a number of the
steps of angiogenesis, including the proliferation and
recruitment of EPCs from BM (1,2). Mean plasma
VEGF levels were higher in the SSc patients (601 pg/ml,
range 81–1,348 pg/ml) than in the healthy controls
(101.3 pg/ml, range undetectable–191 pg/ml) (P 
0.001). Interestingly, mean VEGF levels tended to
be higher in patients with advanced disease than in
those with recent-onset disease (768.2 pg/ml versus
432.8 pg/ml) (Figure 2), although no significant differ-
ences were found in the 2 different subsets of disease.
Figure 1. Flow cytometry evaluation of circulating endothelial progenitor cells (EPCs) in the peripheral blood
(PB) of patients with systemic sclerosis (SSc). A, Levels of EPCs in SSc patients and healthy controls (HC). P 
0.0042 for all SSc patients versus healthy controls; P  0.0001 for patients with early SSc versus patients with late
SSc. B, Correlation of circulating EPC levels with disease duration.
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No correlation was found between the number of circu-
lating EPCs and VEGF levels.
Phenotype analysis of BM low-density MNCs.
We studied BM samples from 14 SSc patients (3 with
early lcSSc, 4 with late lcSSc, 4 with early dcSSc, and 3
with late dcSSc). The mean circulating EPC level was
2,949 cells/ml, with no significant differences between
patients with dcSSc and those with lcSSc. When consid-
ered according to disease duration, SSc patients with
recent-onset disease showed an increased number of
circulating EPCs in comparison with patients with
chronic disease (P  0.003), as observed in the larger
patient group.
In order to determine the phenotype of BM cells
in SSc, samples from 14 patients were analyzed by flow
cytometry. Compared with normal controls, SSc patients
showed a significant decrease in CD133-positive cells
(mean  SD 0.36  0.44% versus 1.23  0.78%; P 
0.01) and a marked increase in P1H12, the surface
marker of mature ECs (mean  SD 1.11  0.6% versus
0.51  0.07%; P  0.007), and in the transforming
growth factor  receptor CD105 (mean  SD 9.89 
5.7% versus 4.45  2.7%; P  0.01). NGFR, the p75
antigen initially identified in the central nervous system
but now known to be expressed in early MSCs, was also
down-regulated in SSc patients (mean  SD 0.73 
0.47% versus 1.4  0.64%; P  0.01). The levels of all
other lineage markers were similar in patients and
controls.
The mean  SD expression of SSc and normal
BM low-density MNC markers is summarized in Table
1. In none of the patients did we find any alteration of
the hemocytometric profile, such as anemia, leukopenia,
or thrombocytopenia, nor did we find other clinical or
hematologic signs indicating the possibility of myelofi-
brosis, which could justify “per se” the BM abnormalities
found.
BM cultures. BM aspirates were studied in order
to evaluate the characteristics of both the hematopoietic
and stromal cell compartments. The cells were cultured
in long-term BM cultures, an in vitro situation that more
closely mimics the BM in vivo. The production of
hematopoietic cells in the supernatant (evaluated by
weekly demipopulation) was always lower in the exam-
ined BM samples from the SSc patients than in those
from the normal controls; stromal growth was also
deficient, and the cells never reached confluence. With
regard to the hematopoietic progenitor evaluations, the
median number of CFUs-GM in SSc BM peaked during
the first week, followed by a decrease in the third week,
whereas the median number in the control long-term
BM cultures initially diminished and reached higher
values between the third and fourth weeks (Figure 3).
EPC separation and EC differentiation of BM
cells. Recovery of CD133-positive cells after immuno-
magnetic separation was always lower in SSc patients
than in normal controls (mean SD 0.12 0.1% versus
0.35  0.18%; P  0.006), with a purity of 88  4.8% as
determined by flow cytometry. In order to induce endo-
thelial differentiation of BM cells, we used a previously
reported technique (21) based on CD133-positive cell
immunoseparation and culture in the presence of
Table 1. Low-density MNC fluorescence-activated cell sorter analysis*
Normal
BM
SSc
BM P
CD45 87.1 9.3 92.2  5.8 –
CD133 1.23 0.78 0.36  0.44 0.01
CD134 2.98 1.53 1.96  0.5 –
Glycophorin A 9.86  6.4 5.48  5 –
CD105 4.45  2.7 9.89  5.7 0.01
CD14 10.2  4.35 6.79  3.4 –
CD3 18.9  7.7 21.1  9.8 –
CD19 4.02  2.65 4.72  3 –
CD117 3.44 1.2 3.55  3.6 –
NGFR 1.4 0.64 0.73  0.47 0.01
P1H12 0.51 0.07 1.11  0.6 0.007
KDR 0.32 0.23 0.41  0.27 –
* Values are the mean  SD percentage of labeled cells in the
mononuclear cell (MNC) fractions of 15 normal bone marrow (BM)
samples and 14 BM samples from patients with systemic sclerosis
(SSc). Only significant P values are shown. NGFR  nerve growth
factor receptor; KDR  kinase insert domain–containing receptor.
Figure 2. Plasma levels of vascular endothelial growth factor (VEGF)
in patients with SSc. Plasma concentrations of VEGF were increased
in patients with SSc compared with those in healthy controls and
tended to be further increased in advanced disease as compared with
recent-onset disease. Values are the mean and SD. P values are versus
healthy controls. See Figure 1 for other definitions.
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VEGF, and a second step of immunomagnetic purifica-
tion using FITC-labeled lectins from UEA-I and anti-
FITC microbeads. This method makes it possible to
obtain a pure EC population with a high proliferative
potential (i.e., a mean expansion capacity that is 2,228
375–fold that of UEA-I–purified cells).
The separated CD133-positive cells were grown
on fibronectin-coated flasks in the presence of VEGF,
bFGF, and IGF-1. After 21 days of culture, the cells had
formed some colonies in only 4 of 14 cases. In 2 of these
cases (both involving cells from patients with late lcSSc),
the colonies were rare and small and did not expand, and
the cells rapidly showed aging and signs of stress (Figure
4); in the other 2 cases (both involving cells from
Figure 3. Evaluation of the ability of bone marrow (BM) from patients with systemic sclerosis (SSc) to produce long-term cultures in vitro.
Low-density mononuclear cells from SSc patients are deficient in the ability to form long-term BM cultures. A, Median number of recovered
nonadherent cells from weekly demipopulation in the supernatant of long-term BM cultures from SSc patients (solid line) and normal controls
(broken line). B, Median number of colony-forming units–granulocyte–macrophage (CFUs-GM), at 1-week intervals, from the nonadherent fraction
of long-term BM cultures from SSc patients (solid line) and normal controls (broken line). C, Median percentage of stroma formation, at 1-week
intervals, in SSc patients (solid line). The area between the broken lines represents the range of stroma formation in long-term BM cultures from
normal controls.
Figure 4. Phase-contrast micrographs of endothelial cell cultures. CD133-positive immunoselected cells after 3
weeks of culture grew in only 4 of 14 systemic sclerosis (SSc) bone marrow (BM) samples, but the colonies from
late SSc BM samples were rare and small and did not expand, and the cells rapidly showed aging and signs of
stress (A). In normal control BM samples (B), the cells reached confluence and had elongated spindle-shaped
morphology with focal areas of cobblestone-like cells. (Original magnification  100.)
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patients with early SSc), there were numerous colonies
of cells characterized by a round central body with some
cytoplasmic projections which, when they reached con-
fluence, consisted of a monolayer of spindle-shaped cells
with some areas of cell aggregates with the typical
“cobblestone” morphology of ECs. However, their puri-
fication with lectins from UEA-I and immunomagnetic
sorting was ineffective; the obtained cells (5.5  103
UEA-I–positive cells) were plated on fibronectin-coated
flasks and cultured in the presence of VEGF, but did not
expand and died within a few days. Their final total
expansion capacity was therefore 350-fold, much lower
than that of the cells from normal controls.
BM stromal cells. In order to evaluate the num-
ber of stromal cell precursors in BM, we used a CFU-F
assay that identifies a population of rapidly-adherent
clonogenic cells with a fibroblastic morphology, which
are capable of extended proliferation and multilineage
differentiation in vitro (23). In the normal control BM
samples, the number of CFUs-F varied but was sig-
nificantly higher than that observed in the 14 SSc BM
samples (36.3  19.4 colonies/1  106 seeded cells
versus 9.8  13 colonies/1  106 seeded cells; P 
0.0019).
In BM, the NGFR antigen defines a subset of
early MSCs with a high proliferative potential, a high
degree of clonogenic efficiency, and the ability to differ-
entiate into multiple mesodermal tissues. In order to
obtain a population of homogeneous and multipotent
MSCs, we positively selected low-affinity anti-NGFR
antibodies as previously reported (23).
After immunomagnetic separation, the mean 
SD recovery of NGFR-positive cells in 8 SSc BM
samples was 0.64  0.3% compared with 1.2  0.6% in
normal BM samples (P  0.029), with a purity of 88 
4.5% as determined by flow cytometry. Phenotype ana-
lysis showed no significant differences in the examined
surface markers except for the overexpression of KDR
in SSc BM samples (23.1 7.8% versus 4.6 1.7%; P
0.002). The clonogenic efficiency of the NGFR-positive
cells was always less in the SSc BM samples than in the
normal control BM samples (7  12.8 colonies/1  105
seeded cells versus 69  61 colonies/1  105 seeded
cells; P  0.01).
NGFR-positive cells are multipotent and capable
of differentiating into mesenchymal tissue lineages, in-
cluding stroma, adipose, and bone. In order to evaluate
their ability to differentiate to fibroblasts, they were
grown in the presence of bFGF, but formed a confluent
layer with a fibroblast morphology in only 3 of 8 cases
(all involving cells from patients with early dcSSc).
Compared with NGFR-positive cells from normal con-
trols, the SSc NGFR-positive cells showed signs of rapid
aging and stress and had a greatly reduced proliferative
capacity (mean  SD fold expansion rate 7.3  103 
1.3  104 versus 6.2  108  8.2  108). When grown in
adipogenic or osteogenic media, the SSc NGFR-positive
cells never differentiated.
We have previously demonstrated that normal
BM NGFR-positive cells are capable of differentiating
to the endothelial phenotype, with total expansion ca-
pacities similar to those of CD133-positive differentiated
ECs (30). When grown in the presence of VEGF, the
SSc NGFR-positive fractions gave rise to endothelial
colonies; once again, however, they were unable to
expand after UEA-I selection, with a total expansion
ability of 26.3  15.7–fold.
Immunocytochemical analysis of ECs. In vitro–
differentiated ECs from early SSc CD133-positive and
NGFR-positive precursors were then analyzed for the
presence of endothelial markers on APAAP-
immunostained cytospin preparations. Like normal ma-
ture ECs, almost all of the cells intensely expressed
CD105 endoglin, P1H12, vWF, VE-cadherin (CD144),
and CD31 (Table 2).
In order to detect the receptors and adhesion
molecules typically modulated by ECs stimulated by
inflammatory cytokines, the cells were incubated with
IL-1 and analyzed immunocytochemically; vWF,
CD62E, and VCAM-1 were up-regulated upon stimula-
tion. Interestingly, in SSc patients, VCAM-1 (CD106),
Table 2. Phenotype characterization of the endothelial differentia-
tion of CD133-positive and NGFR-positive precursors from BM
samples from patients with early SSc and normal controls*
Differentiated
SSc BM ECs
Differentiated
normal BM ECs
vWF 89.7  9.7 99.3 0.7
CD105 98  1 100
VCAM-1 93.3  6.7 0
P1H12 86.7  2.5 100
VE-cadherin 89.3  3.5 99.2 0.6
CD31 93 5.6 99.6 0.5
CD62E 89  3.6 0
CD14 1 0
CD45 1 0
* Values are the mean  SD percentage of labeled cells and are the
results of 6 experiments. The reactivity of differentiated cells was
evaluated by alkaline phosphatase–anti–alkaline phosphatase staining.
The percentage of positive cells was calculated by counting a minimum
of 400 cells at 400 magnification. All markers analyzed were in-
tensely expressed. ECs  endothelial cells; vWF  von Willebrand
factor; VCAM-1  vascular cell adhesion molecule 1 (see Table 1 for
other definitions).
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CD105 endoglin, and CD62E were intensely expressed
even before activation.
DISCUSSION
Many studies have shown that, despite severe
tissue ischemia, new microvessel formation is defective
in SSc patients and is unable to replace the damaged
capillaries (12). Since the results of a number of exper-
imental studies indicate that circulating EPCs are im-
portant to the process of vascular repair (2), we exam-
ined their role in scleroderma vasculogenesis by
investigating the number of EPCs in the PB of patients
with both early- and late-phase SSc, as well as their
number and functional aspects in BM.
The results of the study confirm that EPCs are
detectable in the PB of SSc patients, that their number is
significantly increased in patients with early-phase dis-
ease but not in those with late-phase disease, and that
the levels of VEGF (the main cytokine driving the
differentiation, proliferation, and mobilization of EPCs)
are significantly higher in SSc patients, particularly those
with late-phase disease. Regarding the examination of
BM aspirated from SSc patients, the main results we
obtained indicate the following: 1) regardless of the
disease phase, the BM of all SSc patients examined
contained much fewer and functionally impaired EPCs;
2) only the BM EPCs from patients with early disease
gave rise to some degree of in vitro endothelial differ-
entiation; 3) the stromal compartment of SSc BM was
severely defective in stem cells, and their function was
also impaired; and 4) the surfaces of both endothelial
and stromal progenitors expressed the VEGF receptor,
thus showing that BM is strongly directed toward differ-
entiating into the endothelial lineage.
These findings confirm in an additional group of
patients our preliminary data (13) and only apparently
conflict with those reported by Kuwana et al (14), who
found a reduced number of EPCs with impaired func-
tion in a small series of patients with mainly late-phase
SSc; the conflict with the findings of Kuwana et al is
superficial, in so far as our patients with advanced SSc
also had a limited number of circulating EPCs, thus
indicating a probable exhaustion of the precursor endo-
thelial pool, as has been previously suggested in the case
of other chronic vascular disorders (2,6). This conclusion
is further supported by the increased VEGF levels
observed in our patients, as reported in previous studies
(31,32). Furthermore, the fact that VEGF levels pro-
gressively increased from the early to the late phase of
the disease can be interpreted to be the result of an
impaired target cell response that becomes increasingly
severe as the disease progresses. Interestingly, Dor et al
(33) showed in an experimental animal model that the
overexpression of VEGF induced the formation of new
vessels in adult organs; however, the prolonged exposure
resulted in a chaotic vascular morphology with reduced
blood flow in the newly formed vessels. In addition,
Distler et al (34) indicated that a chronic and uncon-
trolled overexpression of VEGF does occur in SSc and
might significantly contribute to the chaotic capillary
morphology seen in these patients.
The possibility that the target organ of this
powerful angiogenic “push” cannot satisfy the continu-
ous and prolonged peripheral demand is confirmed by
the quantitative impairment of the endothelial stem cell
source in the BM of all of our SSc patients. In addition,
only the BM endothelial progenitors from patients with
early disease led to endothelial differentiation in vitro,
thus suggesting that residual EPC recruitment still takes
place during the early stages of the disease. Taken
together, these findings are consistent with the inverse
correlation we found between the number of PB EPCs
and disease duration. The fact that we found the same
characteristics in all of the SSc BM samples studied
(with no differences related to disease duration) sug-
gests that the exhaustion of resident BM endothelial
progenitors may be a very early step in the course of the
disease.
It has been shown that mesenchymal stem cells
and progenitor cells can differentiate to an endothelial
phenotype and enhance vascularization (35,36), and we
have previously demonstrated that NGFR-positive cells
can differentiate in vitro to the endothelial phenotype
when grown in the presence of VEGF (30). The over-
expression of angiogenic receptors shown by SSc mes-
enchymal progenitors may be an extreme attempt to
increase EPC mobilization from BM, a hypothesis sup-
ported by the fact that in the presence of VEGF, these
multipotent cells preferentially gave rise to endothelial
differentiation, thus suggesting the possible existence of
a response to increasing endothelial requirements
largely involving BM cell populations. Observations that
the transplantation of SSc skin biopsy specimens into
immunodeficient mice or the chick embryo chorioallan-
toic membrane generates increased angiogenic re-
sponses (37,38) also support the hypothesis that the
mechanisms capable of triggering neoangiogenesis can
be up-regulated in SSc and that the impaired repair of
vascular tissue is probably due to an inadequate re-
sponse of SSc BM.
An alternative to the hypothesis that prolonged
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and continuous EC recruitment may exhaust the BM
reservoir of resident EPCs is that disease-related cyto-
toxic mechanisms negatively influence the half-life and
mobilization of BM EPCs. Since EPCs share the pheno-
typic and functional properties of mature ECs (39), they
could be the target of antiendothelial antibodies, which
have been shown to induce apoptotic phenomena and an
activated proinflammatory phenotype in mature SSc
ECs (40,41). The overexpression of surface adhesion
molecules by resting and activated differentiated EPCs
from SSc BM seems to support this hypothesis. Activa-
tion of ECs, as defined by increased expression of
adhesion molecules, has been described in the SSc
microvasculature. E-selectin and intercellular adhesion
molecule 1 (ICAM-1) expression have been found to be
up-regulated in the skin of SSc patients (42–46). In
addition, increased plasma concentrations of soluble
forms of EC surface adhesion molecules, including
ICAM-1, VCAM-1, and E-selectin, have been described
in several studies (47,48).
Although our findings are related to observations
of the in vitro differentiation of EPCs into mature ECs,
they provide further evidence for the relevance of EC
activation (even in SSc BM) and possible grounds for
impaired peripheral incorporation of ECs. Together
with the modulation of cytokine, chemokine, and growth
factor profiles, the additional immunologic abnormali-
ties related to repertoires and activities of B and T cells
are thought to contribute to the inability to resolve
inflammation and the failure of reparative processes
(49).
We can further speculate that the complex im-
pairment of both endothelial and stromal progenitors
observed in the BM of our patients may be due to the
severe generalized microvascular damage associated
with SSc also involving the BM vasculature. We and
other investigators (13,50) have previously reported that
the presence of circulating mature ECs in SSc probably
provides direct evidence of vascular injury leading to EC
shedding. We found an increased number of circulating
mature ECs in the BM of SSc patients compared with
normal controls, and this is consistent with the wide-
spread endothelial damage affecting sclerodermatous
tissues.
In addition to all the possible hypotheses raised
to explain our findings, we must remember that defects
of EC lineages are regarded as the first crucial moment
in the pathogenetic cascade in SSc. In this regard, we can
look at EPC dysfunction as a consequence, rather than a
primary event.
In conclusion, the results of our study do not
allow any definite conclusions concerning the mecha-
nisms accounting for the complex BM scenario in SSc
patients, and it is possible that all of our hypotheses are
simultaneously true. However that may be, BM cells
seem to be crucial in the pathogenesis of SSc and may
have a number of future therapeutic applications. BM
could be a novel target for drugs capable of enhancing
the mobilization and migration of EPCs, and in this
context, recent clinical studies have shown that statins
can significantly increase the number of circulating
EPCs (51,52). Finally, the transplantation of autologous
or exogenous BM-derived endothelial progenitors may
contribute to restoring sclerodermatous tissue vascular-
ization (at least in early SSc), just as recent pioneering
clinical studies have shown that they are effective in
accelerating organ vascularization and repair after isch-
emic events in the limbs, retina, and myocardium (2,53).
To the best of our knowledge, this is the first
study of endothelial progenitors in their original sites,
and we cannot exclude the possibility that similar BM
abnormalities may be found in other chronic vascular
diseases. Our findings provide the first demonstra-
tion that in SSc patients, there is a complex BM micro-
environment impairment involving both the endothelial
and MSC compartments and that this impairment may
be involved in the defective EPC-dependent neoangio-
genesis.
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